



**CCS 2022 Guidelines for Peripheral Arterial Disease**

Panel Member's Relationships with Industry (RWI)

The CCS is committed to preserving the scientific integrity of its Guidelines and Position Statements through transparency and management of relationships with industry (RWI). Panel members must disclose all relationships with industry regardless of relevance to the statement topic (see below). When a potential conflict exists, the affected member must recuse during the formal consensus voting process. For more information on the CCS Guideline Development process, please visit [www.ccs.ca](http://www.ccs.ca).

Affiliations with commercial organizations within the previous two years that may have a direct or indirect connection to the content of this statement.

Member	Consulting Fees/ Honoraria	Clinical Trials	Other Financial Benefit	Relevance to Statement
<b>Primary Panel</b>				
<b>Beth L. Abramson</b>	Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, CHRC, HLS Therapeutics, Novartis, Novo Nordisk, BMS-Pfizer, Servier, Sanofi, BioSyent	None	Jansen has sponsored a prevention fellowship	The relationships include an unrestricted educational grant from multiple sponsors. I am also involved in CME and advisory board activity. Many of these companies are involved in the sale of pharmacologic interventions discussed in this guideline.
<b>Mohammed Al-Omran</b>	None	None	None	
<b>Sonia S. Anand</b>	Bayer AG, Janssen	COMPASS and VOYAGER trial Steering and Executive Committee member	None	Dr. Anand was a member COMPASS and VOYAGER trial Steering and Executive Committee member. She was not a member of the writing team on the antithrombotic therapy in PAD section, although is a co-chair of the overall guidelines
<b>Zaina Albalawi</b>	None	NovoNordisk, Allergan	None	Clinical trials for Semaglutid, and injectable treatment for gastroparesis in individuals with diabetes, unrelated to this guideline.
<b>Thais Coutinho</b>	None	None	None	
<b>Charles de Mestral</b>	Janssen	None	Eli Lilly	Unrelated
<b>Luc Dubois</b>	None	None	None	
<b>Heather L. Gill</b>	None	None	None	

Member	Affiliations with commercial organizations within the previous two years that may have a direct or indirect connection to the content of this statement.			
	Consulting Fees/ Honoraria	Clinical Trials	Other Financial Benefit	Relevance to Statement
Elisa Greco	Gore, Think Research	None	None	I have not been remunerated from the company in more than 2 years. In addition it is strictly for AV access devices and not at all related to Peripheral Vascular Disease. I have consulted in the past 2 years on standardized medical order sets for vascular surgery patients for Think Research.
Randolph Guzman	None	None	None	
Christine Herman	None	Cook for EVAR trial. enrolment done	None	Unrelated
Mohamad A. Hussain	None	None	None	
Victor F. Huckell	HLS	None	None	1. Because of work with CMPA I have declined all Pharmaceutical or Device Company activities for the last three years. I participated in one educational session on a new lipid agent which has no relevance to PAD 2. I am on CMPA Council -- this has no conflict with guideline development, rather is supportive of the process.
Prasad Jetty	Bayer, Boston Scientific, Cook Medical, LeMaitre, Medtronic	None	None	Xarelto (Bayer) is used in the management of PVD and treatment and prevention of MACE and MALE events; the rest are unrelated.
Eric Kaplovitch	None	None	None	
Erin Karlstedt	None	None	None	
Ahmed Kayssi	None	Medtronic	None	I am the primary investigator on an Medtronic-sponsored trial examining the role of cyanoacrylate glue for the treatment of venous leg ulcers. The subject of this study has no relation to peripheral arterial disease.

Member	Affiliations with commercial organizations within the previous two years that may have a direct or indirect connection to the content of this statement.			
	Consulting Fees/ Honoraria	Clinical Trials	Other Financial Benefit	Relevance to Statement
Thomas Lindsay	Bayer, HLS Therapeutics	Cook Canada	None	Bayer: Speaker at conferences (CSVS) on antithrombotic therapy for PAD, HLS Novel lipid lowering agent for cardiovascular disease without specific beneficial effect in PAD. Cook Canada: related to AAA; unrelated to PAD
G.B. John Mancini	Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Boehringer Ingelheim / Eli Lilly Alliance, Esperion, HLS Therapeutics, Janssen, Merck, Novartis, NovoNordisk, Sanofi, Servier	Amgen, NovoNordisk	None	Relevant to PAD are SANOFI, AMGEN, BAYER specifically. The nature of the COI's consist of honoraria for CME lectures, advisory board activities and research/CME grants.
Graham McClure	None	None	None	
M. Sean McMurtry	Bayer	AstraZeneca	None	I attended an add board run by Bayer, the maker of rivaroxaban. This drug has application for PAD patients. This is a small but real financial conflict of interest. I adjudicated events for the THEMIS trial of ticagrelor, which is made by Astra Zeneca and has application for patients with PAD. This is a scientific conflict of interest.
Hassan Mir	None	None	None	
Sudhir Nagpal	None	None	None	
Patrice Nault	None	None	None	
Thang Nguyen	None	None	None	

Member	Affiliations with commercial organizations within the previous two years that may have a direct or indirect connection to the content of this statement.			
	Consulting Fees/ Honoraria	Clinical Trials	Other Financial Benefit	Relevance to Statement
Paul Petrasek	None	None	None	
Luke Rannelli	Bayer	None	None	I have given an education talk on COMPASS and Xarelto 2.5 mg for Bayer in 2018 in regards to its use in peripheral vascular disease.
Derek J. Roberts	None	None	None	
Andre Roussin	None	Bayer	None	I was co-investigator of the VOYAGER-PAD using rivaroxaban and ASA. These drugs are used in certain cases of PAD.
Jacqueline Saw	Abbott, Baylis, Boston Scientific, Gore, FEops	Abbott, Boston Scientific, Edwards	Medtronic, Merck	These are related to left atrial appendage closure. And they are not related to PAD. Also, not related to PAD. Personal stock investments. Not related to PAD.
Kajenny Srivaratharajah	None	None	None	
James Stone	Bayer			Unrelated
David Szalay	Bayer, Cook Canada, Medtronic, HLT Therapeutics	Bayer	None	Co-Investigator in Voyager PAD. Speaker fees for Bayer, Cook and Medtronic. Bayer is relevant to PAD as manufacturer of rivaroxaban which is used in select cases of PAD. Cook and Medtronic manufacture some catheters and devices for the endovascular treatment of PAD.
Darryl Wan	None	None	None	
<b>Secondary Panel</b>				
Heather Cox	None	None	None	
Subodh Verma	Amgen, AstraZeneca, Bayer,Boehringer Ingelheim, Boehringer Ingelheim / Eli Lilly Aliiance, Bristol-Myers Squibb, Eli Lilly, HLS Therapeutics, Janssen, Merck, Novartis, NovoNordisk, Pfizer, Phase Bio Pharmaceuticals, Sanofi	Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Boehringer Ingelheim / Eli Lilly Aliiance, HLS Therapeutics, NovoNordisk, Phase Bio Pharmaceuticals	None	The only relationship that has relevance to PAD Guidelines is Bayer.
Sean Virani	Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Boehringer Ingelheim / Eli Lilly Aliiance, Medtronic, Novartis, NovoNordisk, Otsuka, Pfizer, Servier, Takeda	AstraZeneca, Boehringer Ingelheim, Medtronic, Novartis, Servier	None	Unrelated